CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that an in vivo trial investigating aldoxorubicin, its tumor-targeting conjugate of...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, has named Daniel Levitt, M.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced the presentation today of favorable results from a Phase 1b/2 clinical trial with its ...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2012.
Insiders at these companies have been scooping up shares of their own stock lately.
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the closing of its previously announced underwritten public offering of 9,200,000 shares...
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the sale of an additional 1,200,000 shares of common stock pursuant to the exercise in...
The top 10 open-market insider purchases and sales filed at the SEC Thursday.
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the pricing of its previously announced underwritten public offering.
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today its intention, subject to market and other conditions, to commence a public offering of...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, has initiated an open-label, single-center Phase 1b clinical trial to evaluate the pharmacokinetics of its tumor-targeting ...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announced that favorable data from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin ...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that favorable results from a Phase 1b/2 clinical trial with aldoxorubicin (formerly INNO-206) in patients with ...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2012, and provided a business update.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announced that favorable results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate ...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary ...
For more than two years, former Dallas Maverick basketball player Ray Johnston has been cancer-free.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that the U.
Insiders at these companies have been scooping up shares of their own stock lately.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company’s tumor-targeting linker...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical ...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is expected to join the Russell Microcap® Index when Russell Investments reconstitutes its family of...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, will hold a conference call to discuss favorable clinical results from the Phase 1b/2 clinical trial with INNO-206 in patients ...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate ...
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it received written notification on May 31, 2012 from the NASDAQ Listing Qualifications Department that it ...
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple ...
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients...
